See more : Sonae, SGPS, S.A. (YSON.F) Income Statement Analysis – Financial Results
Complete financial analysis of Xenetic Biosciences, Inc. (XBIOW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Xenetic Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jiiangsu Times Textile Technology Co.,LTD (001234.SZ) Income Statement Analysis – Financial Results
- The Brink’s Company (BCO) Income Statement Analysis – Financial Results
- Teleservice AG (TH51.MU) Income Statement Analysis – Financial Results
- Rainbow Children’s Medicare Limited (RAINBOW.BO) Income Statement Analysis – Financial Results
- CVR Partners, LP (UAN) Income Statement Analysis – Financial Results
Xenetic Biosciences, Inc. (XBIOW)
Industry: Biotechnology
Sector: Healthcare
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.54M | 1.71M | 1.16M | 436.94K | 17.07K | 0.00 | 7.59M | 3.00M | 0.00 | 0.00 | 1.00M | 293.60K |
| Cost of Revenue | 0.00 | 27.04K | 35.48K | 0.00 | 0.00 | 15.83K | 156.12K | 36.45K | 56.12K | 0.00 | 8.44K | 44.84K |
| Gross Profit | 2.54M | 1.68M | 1.13M | 436.94K | 17.07K | -15.83K | 7.43M | 2.96M | -56.12K | 0.00 | 991.57K | 248.77K |
| Gross Profit Ratio | 100.00% | 98.42% | 96.94% | 100.00% | 100.00% | 0.00% | 97.94% | 98.79% | 0.00% | 0.00% | 99.16% | 84.73% |
| Research & Development | 3.49M | 4.77M | 3.16M | 1.73M | 4.89M | 2.88M | 4.06M | 43.74M | 3.43M | 6.32M | 3.06M | 1.94M |
| General & Administrative | 3.56M | 3.65M | 3.74M | 3.40M | 4.73M | 4.39M | 6.94M | 6.69M | 6.39M | 6.60M | 6.55M | 3.45M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 112.00K |
| SG&A | 3.56M | 3.65M | 3.74M | 3.40M | 4.73M | 4.39M | 6.94M | 6.69M | 6.39M | 6.60M | 6.55M | 3.56M |
| Other Expenses | 0.00 | -1.60K | 1.12K | -492.00 | 3.32K | -24.64K | -41.10K | 0.00 | 0.00 | 0.00 | 68.28K | 0.00 |
| Operating Expenses | 7.06M | 8.42M | 6.91M | 5.13M | 9.62M | 7.28M | 11.00M | 50.43M | 9.82M | 12.92M | 9.61M | 5.51M |
| Cost & Expenses | 7.06M | 8.42M | 6.91M | 5.13M | 9.62M | 7.28M | 11.15M | 50.43M | 9.82M | 12.92M | 9.61M | 5.55M |
| Interest Income | 355.76K | 167.15K | 100.47K | 126.17K | 216.98K | 0.00 | 16.54K | 32.00 | 1.69K | 18.96K | 34.86K | 67.67K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.13K | 1.82K | 729.57K | 267.00K | 4.71K | 632.00 | 51.74K |
| Depreciation & Amortization | 0.00 | 27.04K | 35.48K | 28.84K | 27.49K | 15.83K | 23.78K | 36.45K | 56.12K | 88.69K | 52.03K | 104.62K |
| EBITDA | -4.52M | -6.72M | -5.71M | -4.69M | -9.58M | -7.26M | -3.57M | -53.44M | -9.77M | -14.21M | -8.53M | -5.04M |
| EBITDA Ratio | -177.79% | -391.98% | -492.06% | 1,047.61% | -36,872.05% | 0.00% | -47.06% | -1,579.80% | 0.00% | 0.00% | -852.66% | -1,731.71% |
| Operating Income | -4.52M | -6.72M | -5.75M | 4.55M | -12.89M | -7.28M | -3.57M | -47.43M | -9.82M | -12.92M | -8.61M | -6.34M |
| Operating Income Ratio | -177.79% | -393.57% | -495.12% | 1,041.01% | -75,511.71% | 0.00% | -47.05% | -1,581.02% | 0.00% | 0.00% | -861.35% | -2,160.83% |
| Total Other Income/Expenses | 381.14K | 165.56K | 101.59K | 125.68K | 111.80K | -24.13K | -26.37K | -6.78M | -2.69M | -1.38M | -31.95K | -1.18M |
| Income Before Tax | -4.13M | -6.55M | -5.65M | -13.81M | -12.78M | -7.30M | -3.60M | -54.21M | -12.51M | -14.31M | -8.58M | -6.33M |
| Income Before Tax Ratio | -162.78% | -383.87% | -486.36% | -3,161.06% | -74,856.59% | 0.00% | -47.40% | -1,806.87% | 0.00% | 0.00% | -857.92% | -2,155.41% |
| Income Tax Expense | 0.00 | -165.56K | -100.47K | -2.92M | 3.17M | 24.13K | 26.37K | 6.05M | 2.42M | 1.40M | -34.22K | 1.09M |
| Net Income | -4.13M | -6.39M | -5.54M | -10.89M | -15.95M | -7.30M | -3.60M | -54.21M | -12.51M | -14.31M | -8.58M | -6.33M |
| Net Income Ratio | -162.78% | -374.17% | -477.71% | -2,493.11% | -93,460.18% | 0.00% | -47.40% | -1,806.87% | 0.00% | 0.00% | -857.92% | -2,155.41% |
| EPS | -2.71 | -4.49 | -5.39 | -17.04 | -55.92 | -96.58 | -49.78 | -875.41 | -355.34 | -416.91 | -2.84K | -2.09K |
| EPS Diluted | -2.71 | -4.49 | -5.39 | -17.04 | -55.92 | -96.57 | -49.78 | -875.41 | -355.34 | -416.91 | -2.84K | -2.09K |
| Weighted Avg Shares Out | 1.53M | 1.42M | 1.03M | 639.24K | 285.25K | 75.59K | 72.21K | 61.92K | 35.20K | 34.32K | 3.03K | 3.03K |
| Weighted Avg Shares Out (Dil) | 1.53M | 1.42M | 1.03M | 639.24K | 285.25K | 75.60K | 72.21K | 61.92K | 35.20K | 34.32K | 3.03K | 3.03K |
Source: https://incomestatements.info
Category: Stock Reports